- cafead   May 02, 2024 at 11:43: AM
via Gilgamesh Pharmaceuticals has commenced subject dosing in a Phase IIa clinical trial of GM-1020 to treat major depressive disorder (MDD).
This clinical trial aims to evaluate the safety, tolerability, and efficacy of GM-1020 given as single and multiple oral doses.
article source
This clinical trial aims to evaluate the safety, tolerability, and efficacy of GM-1020 given as single and multiple oral doses.
article source